The Effect of Topical Heparin Gel on Reducing Hand–Foot Syndrome Symptoms in Cancer Patients Treated with Capecitabine

Abstract

Rohollah Masumi

Background and Aims Hand–foot syndrome (HFS) is a distinct and relatively frequent toxic skin reaction associated with certain chemotherapy agents, particularly capecitabine. Given the complications of this syndrome and the critical importance of timely and accurate treatment, the present study aims to investigate the efficacy of topical heparin gel in alleviating HFS in cancer patients undergoing treatment with capecitabine.

Methods A total of 40 patients with grade ⩽ 1 HFS associated with capecitabine were randomly assigned to intervention and control groups. The intervention group received heparin sulfate gel four times a day (21 days) along with capecitabine treatment, while the control group received only capecitabine and placebo gel. The changes in the severity of HFS and clinical manifestations, including erythema, swelling, blisters, hyperkeratosis, and bleeding, at baseline and 3 weeks posttreatment were evaluated. The data were subsequently validated by Fisher's or Chi-square tests.

Results At the beginning of the study, there were no significant differences between the two groups regarding disease manifestations. However, after the intervention, a significant difference was observed between the groups in terms of erythema and swelling (p = 0.001). There were no significant differences between the groups in other manifestations, such as blisters, bleeding, and scaling (p = 0.99). Comparison of the degree of HFS in the intervention group showed that 11 patients experienced improvement after the intervention, while all patients in the control group remained at the same degree of syndrome as before the intervention.

Conclusion The management of HFS in cancer treatment includes a combination of prevention, patient education, symptom improvement, and dose-intensity management. According to the results, it can be said that due to the positive effect of topical heparin gel in improving HFS caused by capecitabine and due to the absence of side effects, the use of topical heparin gel is recommended.

Key Points

• Hand–foot syndrome (HFS) is a distinct and relatively frequent toxic skin reaction associated with capecitabine.

• The efficacy of topical heparin gel in alleviating HFS in cancer patients was investigated.

• Topical heparin gel is recommended due to its positive effect in improving HFS caused by capecitabine.

Keywords

topical - heparin sulfate gel - hand–foot syndrome - capecitabine - chemotherapy - cancer

Publikationsverlauf

Eingereicht: 22. August 2024

Angenommen: 12. Dezember 2024

Artikel online veröffentlicht:
24. Januar 2025

• References

• 1 Nikolaou V, Syrigos K, Saif MW. Incidence and implications of chemotherapy related hand-foot syndrome. Expert Opin Drug Saf 2016; 15 (12) 1625-1633
• 2 Rodríguez-Garzotto A, Iglesias-Docampo L, Díaz-García CV. et al. Topical heparin as an effective and safe treatment for patients with capecitabine-induced hand-foot syndrome: results of a phase IIA trial supported by proteomic profiling of skin biopsies. Ther Adv Med Oncol 2022; 14: 17 588359221086911
• 3 Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs 2004; 8 (Suppl. 01) S31-S40
• 4 Abdul Kareem S, Joseph SG, Wilson A, Kareem SA, Kunjumon Vilapurathu J. Incidence and severity of hand-foot syndrome in cancer patients receiving infusional 5-fluorouracil or oral capecitabine-containing chemotherapy regimens. J Oncol Pharm Pract 2024; (e-pub ahead of print)
• 5 Yap Y-S, Kwok L-L, Syn N. et al. Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine–induced hand-foot syndrome: a randomized clinical trial. JAMA Oncol 2017; 3 (11) 1538-1545
• 6 Abdelalim LR, Elnaggar YSR, Abdallah OY. Oleosomes encapsulating sildenafil citrate as potential topical nanotherapy for palmar plantar erythrodysesthesia with high ex vivo permeation and deposition. AAPS PharmSciTech 2020; 21 (08) 310
• 7 Yang Y, Hahn J-H, Kim MS. et al. Therapeutic effect of anti-inflammatory tripeptide cream in hand-foot syndrome/skin reaction related to anticancer drugs: a randomized, double-blind, placebo-controlled pilot trial. Cancer Res Treat 2024; 56 (04) 1050-1057
• 8 Gialaim Purcino Dos Reis FC, Menêses AG, Mazoni SR, Pereira Silveira RCC, Diniz Dos Reis PE, Vasques CI. Topical interventions for preventing hand-foot syndrome resulting from antineoplastic therapy: a scoping review. Rev Esc Enferm USP 2023; 57: e20220107
• 9 Huang XZ, Chen Y, Chen WJ. et al. Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome. Int J Cancer 2018; 142 (12) 2567-2577
• 10 Ding J, Farah MH, Nayfeh T. et al. Targeted therapy–and chemotherapy-associated skin toxicities: systematic review and meta-analysis. Oncol Nurs Forum 2020; 47 (05) E149-E160
• 11 Chanprapaph K, Rutnin S, Vachiramon V. Multikinase inhibitor-induced hand–foot skin reaction: a review of clinical presentation, pathogenesis, and management. Am J Clin Dermatol 2016; 17 (04) 387-402
• 12 Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol 2014; 71 (04) 787-794
• 13 Yamamoto K, Nishiyama S, Kunisada M. et al. Safety and efficacy of bis-glyceryl ascorbate as prophylaxis for hand-foot skin reaction: a single-arm, open-label phase i/ii study (DGA study). Oncologist 2022; 27 (05) e384-e392
• 14 Charalambous A, Tsitsi T, Astras G, Paikousis L, Filippou E. A pilot randomized double-blind, placebo-controlled study on the effects of the topical application of pyridoxine on palmar-plantar erythrodysesthesia (PPE) induced by capecitabine or pegylated liposomal doxorubicin (PLD). Eur J Oncol Nurs 2021; 50: 101866
• 15 Sanches R, Santos F. Hand-foot syndrome in cancer patients: concepts, assessment and management of symptoms. Applied Cancer Research. 2015; 35 (02) 5
• 16 Shinohara N, Nonomura N, Eto M. et al. A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma. Ann Oncol 2014; 25 (02) 472-476
• 17 Burbach G, Zuberbier T. Hand-foot syndrome with tyrosine kinase inhibitor therapy: treatment recommendations [in German]. Urologe A 2013; 52 (11) 1574-1578
• 18 Clark AS, Vahdat LT. Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome: etiology and emerging therapies. Support Cancer Ther 2004; 1 (04) 213-218
• 19 Gomez P, Lacouture ME. Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. Oncologist 2011; 16 (11) 1508-1519
• 20 Collins LE, Troeberg L. Heparan sulfate as a regulator of inflammation and immunity. J Leukoc Biol 2019; 105 (01) 81-92
• 21 Götte M. Syndecans in inflammation. FASEB J 2003; 17 (06) 575-591
• 22 Beurskens DMH, Huckriede JP, Schrijver R, Hemker HC, Reutelingsperger CP, Nicolaes GAF. The anticoagulant and nonanticoagulant properties of heparin. Thromb Haemost 2020; 120 (10) 1371-1383
• 23 Aslani S, Kabiri M, HosseinZadeh S, Hanaee-Ahvaz H, Taherzadeh ES, Soleimani M. The applications of heparin in vascular tissue engineering. Microvasc Res 2020; 131: 104027
• 24 Hsu YR, Nybo R, Sullivan JK. et al. Heparin is essential for a single keratinocyte growth factor molecule to bind and form a complex with two molecules of the extracellular domain of its receptor. Biochemistry 1999; 38 (08) 2523-2534
• 25 Yang BB, Gillespie B, Smith B. et al. Pharmacokinetic and pharmacodynamic interactions between palifermin and heparin. J Clin Pharmacol 2015; 55 (10) 1109-1118
• 26 Kwakman JJM, Elshot YS, Punt CJA, Koopman M. Management of cytotoxic chemotherapy-induced hand-foot syndrome. Oncol Rev 2020; 14 (01) 442
• 27 Lian S, Zhang X, Zhang Y, Zhao Q. Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy agents: a meta-analysis. Clin Exp Dermatol 2021; 46 (04) 629-635
• 28 Zenda S, Ryu A, Takashima A. et al. Hydrocolloid dressing as a prophylactic use for hand-foot skin reaction induced by multitargeted kinase inhibitors: protocol of a phase 3 randomised self-controlled study. BMJ Open 2020; 10 (10) e038276
• 29 Hofheinz R-D, Gencer D, Schulz H. et al. Mapisal versus urea cream as prophylaxis for capecitabine-associated hand-foot syndrome: a randomized phase III trial of the AIO quality of life working group. J Clin Oncol 2015; 33 (22) 2444-2449
• 30 Inokuchi M, Ishikawa S, Furukawa H. et al. Treatment of capecitabine-induced hand-foot syndrome using a topical retinoid: a case report. Oncol Lett 2014; 7 (02) 444-448
• 31 Roayaei M, Najafizadeh N, Sharifi M, Nazeminejad N. The effect of captopril added to standard chemotherapy regimen containing capecitabine in the prevention of hand and foot syndrome in patients with colorectal cancer. Majallah-i Danishkadah-i Pizishki-i Isfahan 2019; 37 (535) 824-831
• 32 Shayeganmehr D, Ramezannia F, Gharib B. et al. Pharmaceutical and clinical studies of celecoxib topical hydrogel for management of chemotherapy-induced hand-foot syndrome. Naunyn Schmiedebergs Arch Pharmacol 2023; 396 (07) 1571-1581
• 33 Li JR, Yang CR, Cheng CL. et al. Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions. Support Care Cancer 2013; 21 (03) 907-911